PDCD1 and Alzheimer disease: Given the fact that various antibodies or small molecules targeting PD-1/PD-1L are already marketed or under development (Kobold et al., 2018; Shaabani et al., 2018), the findings by Baruch et al. triggered considerable interest in immune checkpoint blockade as a novel therapeutic strategy for AD.